Vaccine Injury Claims Face Ticking Clock After EU Ruling

Why It Matters

By fixing the start of the limitation period and enforcing a 10‑year absolute deadline, the ruling shapes how future vaccine injury lawsuits will be timed across the EU, impacting both claimants and manufacturers. It also signals that fault‑based claims may become the primary avenue for older injuries.

Key Takeaways

• EU court sets 3‑year claim start when damage identified
• 10‑year absolute limit applies from product market entry
• Victims may use both product liability and fault‑based routes
• French courts must apply EU deadline, not stabilization rule
• Progressive‑illness claims face tighter time constraints

Pulse Analysis

The European Union’s Product Liability Directive has long offered a uniform framework for compensation when a consumer is harmed by a defective product. The Court of Justice’s recent judgment sharpens that framework by anchoring the three‑year limitation period to the moment a plaintiff can clearly link the damage to the product, discarding the French practice of tying the clock to disease stabilization. In addition, the court reaffirmed the ten‑year absolute bar that expires once the product has been on the market for a decade, regardless of when symptoms emerge. This clarification removes ambiguity that has hampered cross‑border litigation for years.

For claimants, the decision opens a strategic choice between strict liability, which requires no proof of fault, and a fault‑based claim that hinges on the manufacturer’s breach of safety obligations. While the former offers a simpler path, the ten‑year cut‑off means that injuries arising from vaccines or medicines introduced before 2016 are now largely time‑barred under the defect‑based regime. Consequently, plaintiffs like LF are likely to rely on national fault‑based statutes, which often feature longer limitation periods and allow courts to assess evolving medical evidence throughout the proceedings.

The ruling sends a clear signal to pharmaceutical companies that liability exposure is bounded by a predictable timeline, encouraging more rigorous post‑market surveillance and risk‑management practices. Consumer advocacy groups, however, warn that the strict deadlines could leave individuals with slowly manifesting conditions without recourse, potentially eroding public confidence in vaccination programs. Policymakers may need to balance legal certainty for manufacturers with equitable access to compensation, perhaps by considering supplementary compensation schemes or revising the Directive to accommodate progressive illnesses without compromising market stability.